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INTRODUCTION
Although the term “fibromyalgia” (FM) is rel-atively new, the condition characterised by
chronic musculoskeletal pain that is accompanied
by numerous extra-skeletal symptoms has been de-
scribed in the medical literature for many years un-
der different names. The term “fibrositis,” which
was originally used in 1904 by Sir William Gow-
ers to define a type of lumbalgia, became a syn-
onym for diffuse musculoskeletal pain until 1976
(1). In the mid-1970s, Smythe and Moldofsky used
the term “fibrositic syndrome” to describe the pres-
ence of tender points (TPs), sleep disturbances and
other accompanying symptoms such as asthenia
RIASSUNTO
Fin dalla prima descrizione la FM è stata considerata tra le diagnosi più controverse in ambito reumatologico, dal
momento che non tutti accettano l’esistenza della FM come un’entità clinica indipendente. La sensibilità e la specifi-
cità dei criteri diagnostici sono ancora oggetto di discussione tra i vari specialisti (non solo tra i reumatologi), che
sollevano come critica principale il fatto che i criteri dell’American College del 1990 identificano solamente un sub-
set di pazienti non rappresentativo della pratica clinica quotidiana. Inoltre, i sintomi caratteristici della FM sono si-
mili a quelli osservati in altre condizioni cliniche. Negli ultimi anni, questo ha portato a considerare la FM sempre
meno come un’ entità clinica indipendente e sempre più come una possibile manifestazione tipica delle alterazioni del
sistema psico-neuroendocrino (lo spettro dei disturbi affettivi) o del sistema di reazione allo stress (sintomi disfun-
zionali). Recentemente, sono stati sollevati dubbi su queste classificazioni; e attualmente sembra corretto includere la
FM tra le sindromi di “sensibilizzazione del sistema nervoso centrale”, che considerano il meccanismo patogenetico
causa di sindromi muscolari ed extra-muscolari della FM o delle altre sindromi disfunzionali. 
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(2). In the early 1980s, Yunus replaced “fibrositis”
with “fibromyalgia” in order to underline the ab-
sence of phlogistic alterations in the muscle that
were repeatedly reported in published histological
studies (3). In 1990, under the aegis of the Amer-
ican College of Rheumatology (ACR), a multicen-
tre study of 558 patients with fibromyalgia was
conducted with the aim of standardising the diag-
nostic criteria of the syndrome (4). This study
found that the combination of pain induced by 4
kg./cm2 of pressure in at least 11 of the 18 consid-
ered TPs and a history of diffuse musculoskeletal
pain for at least three months provided the most
sensitive, specific and accurate criteria for diag-
nosing both primary and secondary FM. 
However, the use of the 1990 ACR criteria in clin-
ical practice soon highlighted their limitations; in
particular, they were not able to distinguish FM
from other syndromes that are characterised by or-
gan or systemic symptoms without detectable mor-
phological alterations, such as chronic fatigue syn-
drome (CFS) and myofascial syndromes (5-7).
Many of these symptoms overlap to the extent that
the same patient will often satisfy the diagnostic
criteria for two or more syndromes. In 1989, Pope
and Hudson postulated the concept of a “spectrum
of affective disorders” based on the observation
that many of these conditions showed a certain clin-
ical response only to antidepressants (8). Follow-
ing similar reasoning concerning the syndromes’
clinical characteristics and mutual associations, and
considering the most accredited pathogenetic hy-
potheses for each, Yunus coined the definition of a
“spectrum of dysfunctional syndromes” in which
the term “dysfunctional” referred to the supposed
underlying psycho-neuro-immuno-endocrine al-
terations (9). More recently, these attempts at clas-
sification have been questioned and supplanted by
the concept of a “central pain syndrome” or, bet-
ter, “central sensitisation” (10, 11). Central sensi-
tisation is based on the latest experimental evidence
concerning the role that central nervous system
modifications, which are induced by the environ-
ment in genetically predisposed subjects, play in
the onset of many previously defined “algodys-
functional” syndromes, including FM (12).
DEFINITION
In 1989, Wolfe defined FM as “a painful muscu-
loskeletal disorder characterised by core clinical
features that are always present (widespread chron-
ic pain and tenderness), features that are present in
more than 75% of cases (fatigue, non-refreshing
sleep and morning stiffness), and features that are
present in more than 25% of cases (for example,
paresthesia, irritable bowel syndrome and func-
tional disability)” (13). Constitutional symptoms
have not been considered since the 1990 ACR di-
agnostic criteria; and the main symptom that dis-
tinguishes FM is now pain, which must be diffuse
(affecting both sides of the body, above and below
the waist, and the axial skeleton involving at least
one of the cervical, dorsal and lumbar regions of the
spine), chronic (present for at least three months),
and capable of being evoked by pressure at specific
sites (TPs) (4). In our view, developments in our
knowledge of the pathogenetic mechanisms of the
central pain syndromes, together with the reduced
importance of TPs for diagnostic purposes, now al-
low the definition to be reformulated as follows:
“Fibromyalgia is a central sensitisation syndrome
characterised by dysfunctions in the neurocircuits
involving the perception, transmission and pro-
cessing of nociceptive afferents, with the prevalent
manifestation of pain at the level of the muscu-
loskeletal system. In addition to pain, there may be
a multitude of accompanying symptoms (asthenia,
sleep disturbances, abdominal pains…) that are
common to other central sensitisation syndromes.
Particular genetic characteristics and a reduced in-
dividual capacity to tolerate “stressors” predispose
individuals to the onset of the disease”.
DIAGNOSTIC CRITERIA
In 1990, the ACR carried out a study involving 558
FM patients attending 16 centres with the aim of
standardising the syndrome’s diagnostic criteria
(4); this study identified the most sensitive, specific
and accurate criteria for diagnosing FM:
1) A history of widespread pain: chronic, wide-
spread, musculoskeletal pain lasting longer than
three months in all four quadrants of the body
(“widespread pain” was defined as pain above and
below the waist, and on both sides of the body),
with the additional presence of axial skeletal pain
in the cervical spine, anterior chest, thoracic spine
or low back.
2) Pain in 11 of 18 tender sites upon digital pal-
pation: there are 18 TPs that doctors assess to con-
firm the diagnosis of FM (see Figure 1), and ac-
cording to the ACR requirements, a patient must
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endorse at least 11 as painful upon application of
approximately four kg/cm2 of pressure.
As the ACR criteria suggest, a diagnosis of FM re-
quires the “hands-on” evaluation of a patient by a
skilled medical professional, typically a rheuma-
tologist, although other specialists are becoming
quite knowledgeable in this area. Patients are usu-
ally aware of the specific anatomical origins of the
pain in their bodies; however, self-diagnosis is not
advised.
The authors also stated that, from a clinical per-
spective, primary and secondary FM were indis-
tinguishable and, therefore, they proposed abol-
ishing the term “secondary fibromyalgia”. A diag-
nosis of FM may be present concomitant with oth-
er rheumatic diseases, but in this way, the “sec-
ondary” FM remains clinically indistinguishable
from the primary form and is an unnecessary clas-
sification.
In the absence of diagnostic laboratory tests or X-
rays, the ACR diagnostic criteria were a milestone
in the recognition and study of FM. For the first
time, researchers around the world could identify
and study FM patients using standardised measures,
thus enabling comparison of results. In the clinic
setting, patients who had fallen through the cracks
of medical science could finally be diagnosed.
Nevertheless, the criteria were not without their
drawbacks:
• the TP paradigm suggested that FM patients on-
ly experienced pain in anatomically-specific
sites, but later studies (such as those reported by
Granges and Littlejohn in 1993) suggested that
they were sensitive to painful stimuli throughout
the body. Today, widespread body pain is com-
monly associated with FM (14);
• it quickly became evident that tenderness varied
from day to day and from month to month, which
meant that TP counts fluctuated above and below
the required 11 depending on when the count
was made. Furthermore, patients did not always
manifest pain in all four body quadrants: some
had unilateral pain, and/or pain solely in the up-
per or lower half of the body;
• Staud has shown that, although everyone with
FM has TPs, the number of TPs does not reflect
the level of pain patients experience; in short,
TPs do not correlate with pain (15);
• Clauw and Crofford have commented that the
ACR criteria focus only on pain and do not in-
clude many other FM symptoms (fatigue, cogni-
tive disturbance, irritable bowel syndrome, etc.);
as a result, the criteria “fail to capture the essence
of the FM syndrome” and allow for “greater vari-
ability in studies of physiologic mechanisms oth-
er than pain processing” (16);
• the number of TPs is greatly influenced by the
demographic and psychological characteristics
of patients with FM. Women are only 1.5 times
more likely to experience chronic widespread
pain but are 11 times more likely to have 11 or
more TPs, which means that they are approxi-
mately 10 times more likely to satisfy the ACR
criteria. However, most men who experience
chronic widespread pain but are not tender
Figure 1 - Fibromyalgia tender points identified by the American Col-
lege of Rheumatology in 1990 (at digital palpation with an approxi-
mate force of 4 kg).
A) Occiput: bilateral, at the suboccipital muscle insertions.
B) Low cervical: bilateral, at the anterior aspects of the inter-
transverse spaces at C5-C7.
C) Trapezius: bilateral, at the midpoint of the upper border.
D) Supraspinatus: bilateral, at origins, above the scapula spine
near the medial border.
E) Second rib: bilateral, at the second costochondral junction, just
lateral to the junctions on upper surfaces.
F) Lateral epicondyle: bilateral, 2 cm distal to the epicondyles.
G) Gluteal: bilateral, in upper outer quadrants of buttocks in an-
terior fold of muscle. 
H) Greater trochanter: bilateral, posterior to the trochanteric
prominence.
I) Knee: bilateral, at the medial fat pad proximal to the joint line.
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enough to meet FM criteria probably have the
same underlying pathophysiology;
• another unintended consequence of diagnosing
FM on the basis of chronic widespread pain and
at least 11 TPs is that many people with FM ex-
perience high levels of distress. Wolfe has de-
scribed TPs as a “sedimentation rate for distress”
because population-based studies have shown
that TPs are more common in distressed indi-
viduals (17). Distress is considered a combina-
tion of somatic and anxiety and/or depression
symptoms, and it has been assumed that, as TPs
are associated with distress, the same is true of
tenderness (i.e., sensitivity to mechanical pres-
sure). However, recent evidence suggests that the
association is probably due to the standard TP
technique of applying steadily increasing pres-
sure until reaching 4 kg and, in this situation,
people who are anxious or “expectant” have a
tendency to “bail out” and report tenderness;
• TP examinations require skill and, when per-
formed incorrectly (in the wrong place or with
too much or too little digital pressure), they lead
to erroneous results. Unfortunately, the TPs of
FM are also sometimes confused with the trigger
points of myofascial pain syndrome (MPS), and
the two are not uncommonly mistaken for each
other.
To complicate the clinical picture further, FM pa-
tients often have symptoms that overlap with those
of other systemic syndromes (CFS, psychogenic
syndrome, etc) or localised syndromes (MPS, irri-
table bowel syndrome, etc.), and many rheumatol-
ogists doubt that the current 1990 ACR criteria de-
fine a specific disease.
CLINICAL SUBSETS
In 2003, first Hazemeijer and Rasker (18), and then
Ehrlich (19), raised considerable doubts about the
very existence of FM. In particular, Ehrlich con-
sidered it only a mental construct: “When one has
tuberculosis, one has tuberculosis, whether or not
it is diagnosed. The same is true for cancer,
rheumatoid arthritis, hookworm infestation - real-
ly, of the gamut of diseases. But not for FM. No-
one has FM until it is diagnosed.“
However, given the indisputable existence of peo-
ple affected by a central painful syndrome, the pos-
itivist position of Wolfe has a point: “fibromyalgia
will always exist regardless of the name given to
the syndrome” (20).
Setting aside the philosophical issue raised by
Hazemeijer and Rasker concerning the need for a
specific change in the social setting, or “therapeu-
tic dominion”, it has always been clear that pa-
tients diagnosed as having FM on the basis of the
1990 ACR criteria fall into a series of heteroge-
neous subgroups.
Fukuda, et al., studied Air Force veterans from the
first Gulf War in 1990-1991, and defined the com-
plex of symptoms as “chronic multisymptom ill-
ness“ (21). In 1996, Turk, et al. (22), first demon-
strated the existence of “subsets” of FM patients
that could be identified using the Multidimension-
al Pain Inventory (MPI) and that would respond to
different therapies. In addition to psychosocial  and
cognitive factors, they identified a number of spe-
cific neurobiological factors that could better ex-
plain the fundamental mechanism of the pain caus-
ing hyperalgesia and allodynia. 
In 2003, Giesecke, et al. (23), more precisely sep-
arated FM patients on the basis of differences in
their perception of pain and other psychological
factors. They studied 117 FM patients aged 18-60
years (88% women) by evaluating the characteris-
tics and perception of pain (VAS, individual pain
thresholds, the number of tender points), and the
way in which it was interpreted emotionally (anx-
iety, depression and catastrophising) (see Figure
2). They quantitatively analysed six parameters for
each patient (anxiety, depression, catastrophising,
ability to control pain, pain scale, and tenderness
to a light touch) and identified three different clus-
ters.
The most frequent (51.5%) was cluster 1 (long
dashed line), in which all levels of all parameters
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Figure 2 - Subgrouping of fibromyalgia patients on the basis of pres-
sure-pain thresholds and psychological factors (23).
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were medium. This probably represents the ma-
jority of patients who consult a general practition-
er (GP) because of widespread pain and who gen-
erally respond better to prescribed medical thera-
py. 
Cluster 2 (continuous line) represents 32% of the
enrolled patients, a group that was characterised by
high levels of anxiety, depression and cata-
strophising, the lowest level of control over pain,
and significant tenderness to light touch.
Cluster 3 (dotted line) accounted for only 16.5% of
the patients, a group that showed the lowest levels
of anxiety, depression and catastrophising, but al-
so the lowest pain threshold (see Figure 3).
This study showed that patients diagnosed on the
basis of the 1990 ACR criteria fall into different
categories and may have different reactions to the
available therapeutic options.
However, it also strongly suggested that, although
they had represented an unquestioned diagnostic
platform for more than ten years, the 1990 ACR
criteria alone were not sufficient to define FM pa-
tients and, therefore, necessitated further research. 
At the beginning of 2006, the ACR criteria were
used by Katz, et al. (24) to verify their concordance
with the clinical diagnosis alone and with the “sur-
vey criteria.” To this end, they studied 206 patients
evaluated on the basis of TPs using the pooled di-
agnosis of FM (Regional Pain Scale score >8 and
fatigue score >6) and clinical history, and found
that 49% met the criteria for a clinical diagnosis,
29.1% met the 1990 ACR criteria, and 40.3% met
the survey criteria. The clinical and survey criteria
were concordant in 74.8% of cases; the clinical and
1990 ACR criteria were concordant in 75.2% of
cases; and the survey and 1990 ACR criteria were
concordant in 72.3% of cases. Tenderness to light
touch of at least 11 of the 18 ACR TPs was not pre-
sent in the clinical and survey diagnostic criteria but
was shown to be very useful in the clinical diag-
nosis. Therefore, the authors concluded that the
three sets of criteria (clinical, ACR and survey)
were moderately concordant (72-75%). 
As there is no diagnostic “gold standard” for FM,
all of the mentioned criteria are equally useful, and
the survey criteria have the undoubted advantage of
not requiring a physical examination.
DIAGNOSIS
It is clear that a diagnosis of FM cannot be based
exclusively on the 1990 ACR criteria. Many sub-
jects may not have pain throughout the body or at
least 11 TPs upon physical examination, but their
psychological characteristics and associated symp-
toms clearly suggest a form of FM or, at any rate,
a central sensitisation syndrome of which FM is
clearly a part. As there are no specific laboratory
markers, imaging techniques or objective signs,
constitutional symptoms are the only parameters
that can be used.
Characteristics of pain
In clinical practice, FM should be suspected in all
patients describing multifocal pain that has an ori-
gin which is not justified by the presence of tissue
damage or inflammation at the painful sites. In
many cases, the main clinical manifestation is mus-
culoskeletal pain; but it may be much more gener-
alised because it is known that mechanisms of sen-
sory amplification underlie pain of central origin.
This explains why chronic headache, atypical chest
pain, and chronic abdominal or pelvic pain are very
common findings in FM patients; FM should be
suspected in all patients who complain of chronic
pain sine materia at these sites. As pain is the fun-
damental element of FM, it is necessary to inves-
tigate its characteristics and to differentiate it from
pain induced by other diseases. Fibromyalgia pain
is typically diffuse or multifocal, varies in intensi-
ty during the course of the day, and sometimes mi-
grates from one body region to another; its exac-
erbations are influenced by various external phys-
ical and/or psychological factors. These are the
characteristics of central pain, which differ from
the more constant localization and intensity of pe-
ripheral pain. Patients sometimes perceive stimuli
Group 1 (n = 50)
• Low tenderness
• Moderate depression/anxiety
• Moderate catastrophizing
• Moderate control over pain
Group 2 (n = 31)
• High tenderness
• High depression/anxiety
• High catastrophizing
• Low control over pain
Group 3 (n = 16)
• High tenderness
• High depression/anxiety
• High catastrophizing
• High control over pain
Figure 3 - Subgrouping of fibromyalgia patients on the basis of pres-
sure-pain thresholds and psychological factors (23).
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that are usually innocuous, such as wearing clothes,
as painful; if adequately questioned, they fre-
quently report associated paresthesia or dysesthsia
(Tab. I).
Other symptoms
Pain may be accompanied by numerous other
symptoms that are apparently unrelated. Asthenia,
sleep disturbances, weakness, labile attention and
memory deficits, intolerance of cold or heat, visu-
al and hearing disorders, vestibular symptoms, the
sensation of dry mucosae, and inexplicable changes
in weight are only the most frequent. “Allergic”
phenomena such as rhinitis, sinusitis, nasal con-
gestion and lower respiratory airway symptoms are
reported more frequently by FM patients than con-
trols, although these are almost always due to hy-
persensitivity and not immunoglobulin E (IgE)-
mediated immune reactions. The most frequent co-
morbidities in women are dysmenorrhea, intersti-
tial cystitis, vestibulitis and vulvodynia; in men,
non-bacterial prostatitis is most common.
Physical examination
Physical examination is usually negative with the
exception of hyperpathia upon pressure, particu-
larly at the TPs. However, the semiology of the
musculoskeletal system must always be complet-
ed for the purposes of differential diagnosis.
Laboratory tests
Generally, lab tests are not useful except for dif-
ferential diagnosis. One criterion for deciding
which and how many laboratory tests to perform is
the duration of the disease: if the diagnosis was
made several years ago, it is possible to limit the
number of tests, whereas more recent or current
diagnosis may require thorough investigation for
accuracy (Tab. II).
Other investigations
These are not usually necessary unless indicated on
the basis of findings from the physical examination
and laboratory screening (see Figure 4).
DIFFERENTIAL DIAGNOSIS
FM is often part of a wider syndrome encompass-
ing many symptoms from different organs other
than muscles. Its clinical diagnosis is not easy be-
cause fibromyalgia-like symptoms are frequently
found, and differential diagnosis with other caus-
es of chronic pain is essential (Tabs. III, IV). When
Table I - Characteristics of central and peripheral pain.
Central Peripheral
Site Diffuse Localised
Intensity Variable Constant
Stimulus/response ratio Non-proportional Conserved
Modifying factors Environmental and/or psychological factors Mechanical factors
Concomitant sensitivity alterations (dysesthesia/paresthesia) Present Absent
Table II - Laboratory tests recommended at first observation.
Symptom onset <12 months Symptom onset >12 months
ESR ERS
CRP Hemochrome
Hemochrome TSH
ANA
CPK
TSH
Liver and renal function
Figure 4 - Algorithm for the diagnosis of fibromyalgia. Modified from:
Clauw D. Fibromyalgia: defining the disorder and its diagnostic and
treatment approach. www.medscape.com, 2007.
Fibromyalgia-like symptoms >3 months
Normal work-up
Diagnose or “label”
fibromyalgia
Manage accordingly
(may have comorbid
fibromyalgia)
Abnormal work-up
Evaluate for other disorders
Complete physical examination:
• Check ESR, CRP, chemistry panel, TSH
• Avoid ANA, RF unless indicated
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the pain involves a large number of joints, it may
be confused with the widespread pain of FM. The
degree of pain as measured by a visual analogue
scale is not helpful in distinguishing FM from oth-
er conditions such as arthritis or osteoarthritis (25).
Furthermore, as FM can exist in association with
immunoinflammatory diseases, many rheumatic
and non-rheumatic diseases can easily be misdiag-
Causes of focal muscle pain
With swelling or induration
Neoplasm
Trauma (hematoma)
Torn tendon
Ruptured Baker’s cyst
Thrombophlebitis
Infection
Streptoccal myositis
Gas gangrene
Pyomyositis
Trichinosis, hydatid cyst, sparganosis
Painful weakness in children with influenza
Inflammation
Localised nodular myositis
Proliferative myositis
Pseudo-malignant myositis ossificans
Eosinophilic fasciitis
Sarcoidosis (nodular)
Ischemia
Muscle necrosis due to arterial occlusion
Diabetes (thigh muscle infarction)
Embolism (marantic endocarditis)
Azotemic hyperparathyroidism 
Toxic and metabolic disorders
Acute alcoholic myopathy
Myoglobinuria in drug-induced coma
Drug-induced damage
Effort-induced muscle damage (in normal subjects 
or subjects with metabolic myopathies)
Motor unit hyperactivity (stiff man syndrome, tetanus, 
strychnine poisoning) 
Without swelling or induration
Effort myalgia
Normal subjects
Claudicatio intermittens
Metabolic myopathies
Acute brachialgia
Ischemic mononeuropathy
Parkinsonism
Resting leg pain of obscure cause
Growing pains
Restless legs
Painful legs and tips of the fingers
Idiopathic leg pain
Causes of generalised muscle pain
With muscle weakness
Inflammation (dermatomyositis and polymyositis)
Infection
Toxoplasmosis
Trichinosis
Toxic myopathy (viral infections, leptospirosis, 
Gram-negative infections, toxic shock syndrome, 
Kawasaki’s syndrome)
Poliomyelitis
Toxic and metabolic disorders 
Acute alcoholic myopathy 
Hypophosphatemia 
Potassium deficiency
Total parenteral nutrition
Carcinoma-induced necrotic myopathy
Hypothyroid myopathy
Drugs (e-aminocaproic acid, clofibrate, emetine)
Carnitine palmitoyltransferase deficiency
Amyloidosis
Bone pain and myopathy (osteomalacia, 
hyperparathyroidism)
Acute polyneuropathy (Guillain-Barré syndrome, porphyria)
Without muscle weakness
Rheumatic polymyalgia
Painful muscle fasciculation syndrome
Myalgia in infections or fever
Myalgia in collagenovascular disease
Discontinuation of steroids
Hypothyroidism
Primary myalgia
Fabry’s disease
Parkinsonism
Table III - Possible causes of muscle pain.
Modified from: Layzer RB: Muscle pain, cramps and fatigue. In Engel AG, Banker BQ (eds.): Myology. New York, McGraw-Hill, 1986, pp. 1907-1922.
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nosed as FM. A recent study (26) has provided
some evidence concerning inaccuracy in diagnos-
ing FM in a cohort of patients referred to a rheuma-
tology clinic: FM was confirmed in only 34% of
patients presenting with musculoskeletal pain, with
a 66% diagnostic error rate. TPs (p<0.0001) and fa-
tigue (p=0.0003) were the symptoms that discrim-
inated FM from the non-FM patients, whereas pro-
longed early morning stiffness was a clinically dis-
criminating feature of the non-FM patients (al-
though this feature was present in a quarter of those
with FM). Given the high rate of error in diagnos-
ing FM, the authors concluded that a wider spec-
trum of diseases should be considered in the dif-
ferential diagnosis of ill-defined aches and pain.
There is a general agreement about this. Rheumat-
ic autoimmune diseases such as Systemic Lupus
Erythematosus (SLE), Sjögren’s syndrome, other
connective tissue diseases (CTDs), rheumatoid
arthritis (RA) and spondyloarthritis, and non-
rheumatic diseases such as hypothyroidism, ane-
mia, Lyme disease, hepatitis C virus infection
(HCV), chronic fatigue syndrome (CFS) and occult
malignancy, are all possible etiologies for symp-
toms of vague and diffuse musculoskeletal pain as-
sociated with marked fatigue (27).
The differential diagnosis of SLE and FM may pose
a dilemma as such patients may have common
symptoms (28, 29), including musculoskeletal pain,
fatigue and stiffness, cold-induced vasospasm, sic-
ca symptoms, cognitive dysfunction, and depres-
sion (30, 31). Furthermore, some studies have re-
ported the coexistence of SLE and FM. Middleton
(30) and Morand (31), respectively, found a preva-
lence of FM of 22% and 25% in their groups of SLE
patients, and Akkasilpa (32) reported the presence
of more than 11/18 TPs in 17% of 173 SLE pa-
tients. Differential diagnosis is more difficult when
a patient with FM is positive for antinuclear anti-
bodies (ANAs) because, although sensitive, ANA
positivity is not specific for SLE or CTDs (28). In
a recent study of 450 FM patients, Kotter did not
find any significant difference in the frequency of
ANAs or thyroid antibodies between patients and
controls, and concluded that there is no predisposi-
tion for autoimmune diseases in FM; on the other
hand, in order not to overlook early CTD, other spe-
cific differential diagnostic tests should be consid-
ered in ANA-positive FM patients (33). Finally, FM
does not correlate with SLE disease activity, but the
clinical features of FM may contribute to a misin-
terpretation of such activity (34). 
FM is mainly discussed as an early symptom of
Sjogren’s syndrome in the literature, but the data are
rather controversial (35). In FM patients with Sjö-
gren’s syndrome features, Schirmer and Saxon’s
test, salivary gland biopsies, capillary microscopy
and specific laboratory tests should be considered
for the purposes of differential diagnosis (33, 34).
Patients with Sjögren’s syndrome probably have
concomitant FM, which may dominate their com-
plaints and, thus, be diagnosed before Sjögren’s
syndrome. This has also been described in the case
of other inflammatory rheumatic conditions such
as RA and spondylitis in which pain, fatigue and
stiffness are common (30, 34, 36, 37). 
Many other rheumatic and non-rheumatic diseases
may be confused with FM (28). Polymyalgia
rheumatica is characterised by widespread pain and
morning stiffness, but the hallmark is the erythro-
cyte sedimentation rate (ESR); it is reported that
ESR was not increased in 20% of patients (38-39).
Inflammatory myopathies and osteomalacia may
be confused with FM, but a correct diagnosis can
be helped by clinical findings, laboratory findings
and diagnostic procedures (creatine kinase levels,
muscle biopsy, hypophosphatemia, and radi-
ographic changes) (40, 41).
Other medical diseases associated with widespread
pain should be considered in the differential diag-
nosis of FM (25) as they may be confused with FM
or truly overlap it. Patients with thyroid dysfunction
may experience profound fatigue, muscle weakness
and general achiness (28); and a recent study of
thyroid abnormalities and autoimmunity in FM pa-
tients found the presence of thyroid antibody in
41% of the patients, thus, suggesting an association
between autoimmune thyroiditis and FM (42).
In a cohort of 287 patients with Lyme disease that
was followed for 3.5 years, 8% of patients had as-
sociated FM; although the differential diagnosis is
based on serological testing, Lyme disease may
trigger FM (43).
FM has been reported in 5-19% of patients with
HCV infections. However, it is still debated
Table IV - Conditions that simulate fibromyalgia.
Common Less common
Hypothyroidism Hepatitis C
Polymyalgia rheumatica Sleep apnea
Early in course of autoimmune 
disorders: e.g. rheumatoid arthritis 
or SLE Chiari malformation
Sjogren’s syndrome
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whether HCV infection is associated with FM,
since there is no proof of an epidemiological link
between the two (44). 
CFS frequently overlaps FM (Tab. VI). More than
70% of FM patients have CFS symptoms, and the
patients who meet the criteria for both FMS and
CFS have a worse overall health status (45).
Myofascial pain syndrome has been defined as
chronic pain accompanied by trigger points (TrPs)
in one or more muscles or group of muscles (Tab.
V). TrPs may easily be mistaken for TPs and, thus,
lead to the overdiagnosis of FM; therefore, physi-
cians must be able to distinguish TrPs and TPs with
the aid of a pain drawing (25). 
CONCLUSIONS
In the light of current knowledge, we can define
FM as a “central sensitisation syndrome charac-
terised by dysfunction in the neurocircuits involv-
ing the perception, transmission and processing of
nociceptive afferents, with the prevalent manifes-
tation of pain at the level of the musculoskeletal
system”.
Together with pain, which is characterised by hy-
peralgesia and allodynia, symptoms of debilitating
fatigue, disrupted or non-restorative sleep, func-
tional bowel disturbances, and a variety of neu-
ropsychiatric problems including cognitive dys-
function, anxiety and depressive symptoms com-
bine to define FM (46). Women are the most af-
fected, and the disease has a familial connection
linked to genetic variances in the serotonin,
dopamine and catecholamine intracerebral system
(47). The physical symptoms of FM express them-
selves primarily in the presence of a psychological
condition that reduces the individual capacity to
tolerate stessors (48).
Despite widespread criticism, the diagnostic crite-
ria of FM are still based on the 1990 ACR recom-
mendations, which require a specific case history
(widespread pain lasting more than three months,
sleep disturbance, debilitating fatigue, paresthesia),
and tenderness upon pressure (4 kg/cm2) in at least
11 of the 18 TPs distinguishing the disease, on both
sides of the body and simultaneously above and be-
low the waist. On the basis of these diagnostic cri-
Table V - Clinical criteria for a diagnosis of myofascial pain syndrome caused by active trigger points.
To make a clinical diagnosis of myofascial pain syndrome, the findings should include the five main criteria and at least one of the three
minor criteria. The five main criteria are:
1. Reported symptom of regional pain.
2. Symptoms of pain or altered sensation in the expected distribution, or pain transferred from a myofascial trigger point.
3. Palpable tense fascia in an accessible muscle.
4. Point of great tenderness along the tense fascia.
A certain limitation in the amplitude of movement, when measurable.
The three minor criteria are:
1. Clinical symptom of pain or altered sensitivity reproduced by pressure on the tender point.
2. Provocation of local contraction response by means of sharp transversal palpation on the tender point, or the insertion of a needle in
the tender point of the tense fascia.
3. Pain relived by lengthening (stretching) the muscle or by injecting the tender point (trigger point).
Note: Additional symptoms are often present, such as sensitivity to the weather, disturbed sleep and depression, but they are not diagnostic because they may be attributable to
chronic severe pain perpetuated by numerous mechanical and/or systemic factors. From: Simons AG: Muscular pain syndromes. In : Friction JR, Awad EA (eds.), Advances in
Pain Research and Therapy, Vol. 17: Myofascial Pain and Fibromyalgia. New York, Raven Press, 1990, p. 18.
Table VI - Diagnostic criteria for chronic fatigue syndrome.
• Clinically ascertained, persistent, recurrent and unexplai-
nable chronic fatigue
• of recent onset or temporally identifiable
• not due to an ongoing period of effort
• not relievd by rest
• occupationally, socially or personally disabling.
The concomitant presence of at least four of the following
symptoms, each of which must have been present continuou-
sly or have recurred occasionally for at least six or more con-
secutive months of disease, and not prevailing over the fati-
gue:
• patient report of a deterioration in short-term memory that
is sufficiently severe as to cause a reduction in previous
working, scholastic, social or personal activities
• pharyngodynia
• cervical or axillary lymphadenopathy
• muscle pain
• polyarticular pain without tumefaction or reddening
• headaches with new characteristics or of different severity
• unrefreshing sleep
• malaise following effort and lasting more than 24 hours. 
12 M. Cazzola et al.
teria, three subsets of FM patients can be identified
based on individual pain-emotional and neurobio-
logical characteristics that respond differently to
specific therapeutic strategies.
Many common musculoskeletal conditions can
mimic FM and, thus, may be misdiagnosed as FM.
Moreover, many patients do not completely satis-
fy the FM criteria; rather, they only present with a
few symptoms. FM may co-occur or overlap sev-
eral rheumatic and non-rheumatic conditions. In
patients with widespread pain and fatigue, it is nec-
essary to rule out the presence of any other med-
ical condition or disease known to cause these
symptoms (27, 28). 
A simple and rational approach to evaluating these
patients should include a complete clinical history,
a physical examination and laboratory tests; and
patients with a history that suggests FM should un-
dergo further investigation of their vital signs; TPs;
joints and tendons; neurological, abdominal and
thyroid status; and signs of connective tissue or
other concomitant diseases (49). Laboratory as-
sessments should include a complete blood cell
count for common anemias, infections and bone
marrow diseases. Although ESR and C-reactive
protein are non-specific, they can help to confirm
systemic inflammation or infection. Patients pre-
senting with fatigue and widespread pain should
undergo routine thyroid function tests. A standard
chemistry panel (liver and kidney function, serum
fasting glucose, blood lipids) is useful to evaluate
overall systemic health. If the physical examination
findings suggest joint involvement and soft tissue
inflammation, additional serological tests such as
rheumatoid factor, ANAs or others should be per-
formed (27). There is agreement that the differen-
tial diagnosis of FM should be ruled out as far as
possible by adding a number of simple blood tests
to the physical examination, which would be jus-
tified if the history and physical examination sug-
gest another concomitant or associated condition.
Finally, FM should be diagnosed on the basis of its
own characteristics and not just by exclusion; the
presence of a concomitant disease such as arthritis
or hypothyroidism does not exclude a diagnosis of
FM (25,49).
SUMMARY
Ever since it was first defined, fibromyalgia (FM) has been considered one of the most controversial diagnoses in the
field of rheumatology, to the point that not everybody accepts its existence as an independent entity. The sensitivity
and specificity of the proposed diagnostic criteria are still debated by various specialists (not only rheumatologists),
whose main criticism of the 1990 American College of Rheumatology criteria is that they identify subsets of particu-
lar patients that do not reflect everyday clinical reality. Furthermore, the symptoms characterising FM overlap with
those of many other conditions classified in a different manner. Over the last few years, this has led to FM being con-
sidered less as a clinical entity and more as a possible manifestation of alterations in the psychoneuroendocrine sys-
tem (the spectrum of affective disorders) or the stress reaction system (dysfunctional symptoms). More recently, doubts
have been raised about even these classifications; and it now seems more appropriate to include FM among the cen-
tral sensitisation syndromes, which identify the main pathogenetic mechanism as the cause of skeletal and extra-skele-
tal symptoms of FM and other previously defined “dysfunctional” syndromes.
Key words - Diagnosis, ACR criteria, overlap syndrome, dysfunctional syndromes.
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